Please use this identifier to cite or link to this item: https://doi.org/10.21256/zhaw-3135
Publication type: Article in scientific journal
Type of review: Peer review (publication)
Title: Manufacturing human mesenchymal stem cells at clinical scale : process and regulatory challenges
Authors: Jossen, Valentin
van den Bos, Christian
Eibl-Schindler, Regine
Eibl, Dieter
et. al: No
DOI: 10.21256/zhaw-3135
10.1007/s00253-018-8912-x
Published in: Applied Microbiology and Biotechnology
Volume(Issue): 102
Issue: 9
Page(s): 3981
Pages to: 3994
Issue Date: 2018
Publisher / Ed. Institution: Springer
ISSN: 0175-7598
1432-0614
Language: English
Subjects: Advanced therapeutic medicinal product; Allogeneic; Good manufacturing practice; Human mesenchymal stem cell; Microcarrier; Single-use device; Bioreactor; Cell culture technique; Mesenchymal stem cell; Biomedical technology assessment; Cell- and tissue-based therapy
Subject (DDC): 660.6: Biotechnology
Abstract: Human mesenchymal stem cell (hMSC)-based therapies are of increasing interest in the field of regenerative medicine. As economic considerations have shown, allogeneic therapy seems to be the most cost-effective method. Standardized procedures based on instrumented single-use bioreactors have been shown to provide billion of cells with consistent product quality and to be superior to traditional expansions in planar cultivation systems. Furthermore, under consideration of the complex nature and requirements of allogeneic hMSC-therapeutics, a new equipment for downstream processing (DSP) was successfully evaluated. This mini-review summarizes both the current state of the hMSC production process and the challenges which have to be taken into account when efficiently producing hMSCs for the clinical scale. Special emphasis is placed on the upstream processing (USP) and DSP operations which cover expansion, harvesting, detachment, separation, washing and concentration steps, and the regulatory demands.
URI: https://digitalcollection.zhaw.ch/handle/11475/17743
Fulltext version: Published version
License (according to publishing contract): CC BY 4.0: Attribution 4.0 International
Departement: Life Sciences and Facility Management
Organisational Unit: Institute of Chemistry and Biotechnology (ICBT)
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
File Description SizeFormat 
Jossen2018_Article_ManufacturingHumanMesenchymal.pdf1.34 MBAdobe PDFThumbnail
View/Open
Show full item record
Jossen, V., van den Bos, C., Eibl-Schindler, R., & Eibl, D. (2018). Manufacturing human mesenchymal stem cells at clinical scale : process and regulatory challenges. Applied Microbiology and Biotechnology, 102(9), 3981–3994. https://doi.org/10.21256/zhaw-3135
Jossen, V. et al. (2018) ‘Manufacturing human mesenchymal stem cells at clinical scale : process and regulatory challenges’, Applied Microbiology and Biotechnology, 102(9), pp. 3981–3994. Available at: https://doi.org/10.21256/zhaw-3135.
V. Jossen, C. van den Bos, R. Eibl-Schindler, and D. Eibl, “Manufacturing human mesenchymal stem cells at clinical scale : process and regulatory challenges,” Applied Microbiology and Biotechnology, vol. 102, no. 9, pp. 3981–3994, 2018, doi: 10.21256/zhaw-3135.
JOSSEN, Valentin, Christian VAN DEN BOS, Regine EIBL-SCHINDLER und Dieter EIBL, 2018. Manufacturing human mesenchymal stem cells at clinical scale : process and regulatory challenges. Applied Microbiology and Biotechnology. 2018. Bd. 102, Nr. 9, S. 3981–3994. DOI 10.21256/zhaw-3135
Jossen, Valentin, Christian van den Bos, Regine Eibl-Schindler, and Dieter Eibl. 2018. “Manufacturing Human Mesenchymal Stem Cells at Clinical Scale : Process and Regulatory Challenges.” Applied Microbiology and Biotechnology 102 (9): 3981–94. https://doi.org/10.21256/zhaw-3135.
Jossen, Valentin, et al. “Manufacturing Human Mesenchymal Stem Cells at Clinical Scale : Process and Regulatory Challenges.” Applied Microbiology and Biotechnology, vol. 102, no. 9, 2018, pp. 3981–94, https://doi.org/10.21256/zhaw-3135.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.